Alex Zhavoronkov, PhD, is the founder and CEO of Insilico Medicine, a leader in generative artificial intelligence technologies for drug discovery and biomarker development. He founded the company in 2014 and applied AI technologies to analyze a wide range of data types, including anti-aging, disease mechanisms, target identification, and signaling pathway modeling. In 2016, he pioneered the application of key technologies in Generative Adversarial Networks (GANs) and Reinforcement Learning (RL) to drug discovery, discovering novel targets and generating novel molecules with satisfied properties.

Prior to Insilico, Dr. Zhavoronkov worked in senior roles at ATI Technologies (acquired by AMD), NeuroGNeuroinformatics, Biogerontology Research Foundation and Deep Longevity. Since 2012 he has published over 200 peer-reviewed research papers, and three books. He serves on the advisory or editorial boards of Trends in Molecular Medicine, Aging Research Reviews, Aging, Frontiers in Genetics, and npj Aging and co-chairs the Annual Aging Research, Drug Discovery and AI Forum, the largest global non-profit conference in the pharmaceutical industry. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.

With his combined background in biomedicine and computer technology, Dr. Zhavoronkov has been recognized by Deep Knowledge Analytics in 2019 as one of the top 100 AI leaders in drug discovery and advanced healthcare globally and has been selected as one of Clarivate's Global Highly Cited Scientists for 2022.

Fortune, Medicine, CEO, Chief Executive Officer (CEO), Science, Biotechnology, Aging, Business Founders, Artificial Intelligence, Pharmaceutical, Research Scientist, Robotics, Blockchain Health,